Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials
Abstract Background Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or early discontinuation. We aimed to estimate the effects of hydroxychloroquine and chloroquine on survival in COVID-19 from all currently available RCT evidence, published and unpublished. Methods: Rapid meta-analysis of ongoing, completed, or discontinued RCTs on hydroxychloroquine or chloroquine treatment for any COVID-19 patients (protocol: <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://osf.io/QESV4/">https://osf.io/QESV4/</jats:ext-link>). We systematically identified published and unpublished RCTs by September 14, 2020 (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, PubMed, Cochrane COVID-19 registry). All-cause mortality was extracted (publications/preprints) or requested from investigators and combined in random-effects meta-analyses, calculating odds ratios (ORs) with 95% confidence intervals (CIs), separately for hydroxychloroquine/chloroquine. Prespecified subgroup analyses included patient setting, diagnostic confirmation, control type, and publication status.Results Sixty-two trials were potentially eligible. We included 16 unpublished trials (1596 patients) and 10 publications/preprints (6317 patients). The combined summary OR on all-cause mortality for hydroxychloroquine was 1.08 (95%CI: 0.99, 1.18; I2=0%; 24 trials; 7659 patients) and for chloroquine 1.77 (95%CI: 0.15, 21.13, I2=0%; 4 trials; 307 patients). We identified no subgroup effects.Conclusions We found no benefit of hydroxychloroquine or chloroquine on the survival of COVID-19 patients. For hydroxychloroquine, the confidence interval is compatible with increased mortality (OR 1.18) or negligibly reduced mortality (OR 0.99). Findings have unclear generalizability to outpatients, children, pregnant women, and people with comorbidities..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 18. Feb. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2020.09.16.20194571 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI018798373 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI018798373 | ||
| 003 | DE-627 | ||
| 005 | 20230429094356.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200924s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.09.16.20194571 |2 doi | |
| 035 | |a (DE-627)XBI018798373 | ||
| 035 | |a (DE-599)biorXiv10.1101/2020.09.16.20194571 | ||
| 035 | |a (biorXiv)10.1101/2020.09.16.20194571 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Axfors, Cathrine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or early discontinuation. We aimed to estimate the effects of hydroxychloroquine and chloroquine on survival in COVID-19 from all currently available RCT evidence, published and unpublished. Methods: Rapid meta-analysis of ongoing, completed, or discontinued RCTs on hydroxychloroquine or chloroquine treatment for any COVID-19 patients (protocol: <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://osf.io/QESV4/">https://osf.io/QESV4/</jats:ext-link>). We systematically identified published and unpublished RCTs by September 14, 2020 (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, PubMed, Cochrane COVID-19 registry). All-cause mortality was extracted (publications/preprints) or requested from investigators and combined in random-effects meta-analyses, calculating odds ratios (ORs) with 95% confidence intervals (CIs), separately for hydroxychloroquine/chloroquine. Prespecified subgroup analyses included patient setting, diagnostic confirmation, control type, and publication status.Results Sixty-two trials were potentially eligible. We included 16 unpublished trials (1596 patients) and 10 publications/preprints (6317 patients). The combined summary OR on all-cause mortality for hydroxychloroquine was 1.08 (95%CI: 0.99, 1.18; I2=0%; 24 trials; 7659 patients) and for chloroquine 1.77 (95%CI: 0.15, 21.13, I2=0%; 4 trials; 307 patients). We identified no subgroup effects.Conclusions We found no benefit of hydroxychloroquine or chloroquine on the survival of COVID-19 patients. For hydroxychloroquine, the confidence interval is compatible with increased mortality (OR 1.18) or negligibly reduced mortality (OR 0.99). Findings have unclear generalizability to outpatients, children, pregnant women, and people with comorbidities. | ||
| 700 | 1 | |a Schmitt, Andreas M. |e verfasserin |4 aut | |
| 700 | 1 | |a Janiaud, Perrine |e verfasserin |4 aut | |
| 700 | 1 | |a van ’t Hooft, Janneke |e verfasserin |4 aut | |
| 700 | 1 | |a Abd-Elsalam, Sherief |e verfasserin |4 aut | |
| 700 | 1 | |a Abdo, Ehab F. |e verfasserin |4 aut | |
| 700 | 1 | |a Abella, Benjamin S. |e verfasserin |4 aut | |
| 700 | 1 | |a Akram, Javed |e verfasserin |4 aut | |
| 700 | 1 | |a Amaravadi, Ravi K. |e verfasserin |4 aut | |
| 700 | 1 | |a Angus, Derek C. |e verfasserin |4 aut | |
| 700 | 1 | |a Arabi, Yaseen M. |e verfasserin |4 aut | |
| 700 | 1 | |a Azhar, Shehnoor |e verfasserin |4 aut | |
| 700 | 1 | |a Baden, Lindsey R. |e verfasserin |4 aut | |
| 700 | 1 | |a Baker, Arthur W. |e verfasserin |4 aut | |
| 700 | 1 | |a Belkhir, Leila |e verfasserin |4 aut | |
| 700 | 1 | |a Benfield, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Berrevoets, Marvin A.H. |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Cheng-Pin |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Tsung-Chia |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Shu-Hsing |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Chien-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Wei-Sheng |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Yehuda Z. |e verfasserin |4 aut | |
| 700 | 1 | |a Cowan, Lisa N. |e verfasserin |4 aut | |
| 700 | 1 | |a Dalgard, Olav |e verfasserin |4 aut | |
| 700 | 1 | |a de Almeida e Val, Fernando F. |e verfasserin |4 aut | |
| 700 | 1 | |a de Lacerda, Marcus V.G. |e verfasserin |4 aut | |
| 700 | 1 | |a de Melo, Gisely C. |e verfasserin |4 aut | |
| 700 | 1 | |a Derde, Lennie |e verfasserin |4 aut | |
| 700 | 1 | |a Dubee, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Elfakir, Anissa |e verfasserin |4 aut | |
| 700 | 1 | |a Gordon, Anthony C. |e verfasserin |4 aut | |
| 700 | 1 | |a Hernandez-Cardenas, Carmen M. |e verfasserin |4 aut | |
| 700 | 1 | |a Hills, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Hoepelman, Andy I.M. |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yi-Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Igau, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Ronghua |e verfasserin |4 aut | |
| 700 | 1 | |a Jurado-Camacho, Felipe |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Khalid S. |e verfasserin |4 aut | |
| 700 | 1 | |a Kremsner, Peter G |e verfasserin |4 aut | |
| 700 | 1 | |a Kreuels, Benno |e verfasserin |4 aut | |
| 700 | 1 | |a Kuo, Cheng-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Le, Thuy |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yi-Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Wu-Pu |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Tse-Hung |e verfasserin |4 aut | |
| 700 | 1 | |a Lyngbakken, Magnus Nakrem |e verfasserin |4 aut | |
| 700 | 1 | |a McArthur, Colin |e verfasserin |4 aut | |
| 700 | 1 | |a McVerry, Bryan J. |e verfasserin |4 aut | |
| 700 | 1 | |a Meza-Meneses, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Monteiro, Wuelton M. |e verfasserin |4 aut | |
| 700 | 1 | |a Morpeth, Susan C. |e verfasserin |4 aut | |
| 700 | 1 | |a Mourad, Ahmad |e verfasserin |4 aut | |
| 700 | 1 | |a Mulligan, Mark J. |e verfasserin |4 aut | |
| 700 | 1 | |a Murthy, Srinivas |e verfasserin |4 aut | |
| 700 | 1 | |a Naggie, Susanna |e verfasserin |4 aut | |
| 700 | 1 | |a Narayanasamy, Shanti |e verfasserin |4 aut | |
| 700 | 1 | |a Nichol, Alistair |e verfasserin |4 aut | |
| 700 | 1 | |a Novack, Lewis A. |e verfasserin |4 aut | |
| 700 | 1 | |a O’Brien, Sean M. |e verfasserin |4 aut | |
| 700 | 1 | |a Okeke, Nwora Lance |e verfasserin |4 aut | |
| 700 | 1 | |a Perez, Léna |e verfasserin |4 aut | |
| 700 | 1 | |a Perez-Padilla, Rogelio |e verfasserin |4 aut | |
| 700 | 1 | |a Perrin, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Remigio-Luna, Arantxa |e verfasserin |4 aut | |
| 700 | 1 | |a Rivera-Martinez, Norma E. |e verfasserin |4 aut | |
| 700 | 1 | |a Rockhold, Frank W. |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez-Llamazares, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Rolfe, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Rosa, Rossana |e verfasserin |4 aut | |
| 700 | 1 | |a Røsjø, Helge |e verfasserin |4 aut | |
| 700 | 1 | |a Sampaio, Vanderson S. |e verfasserin |4 aut | |
| 700 | 1 | |a Seto, Todd B. |e verfasserin |4 aut | |
| 700 | 1 | |a Shehzad, Muhammad |e verfasserin |4 aut | |
| 700 | 1 | |a Soliman, Shaimaa |e verfasserin |4 aut | |
| 700 | 1 | |a Stout, Jason E. |e verfasserin |4 aut | |
| 700 | 1 | |a Thirion-Romero, Ireri |e verfasserin |4 aut | |
| 700 | 1 | |a Troxel, Andrea B. |e verfasserin |4 aut | |
| 700 | 1 | |a Tseng, Ting-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Turner, Nicholas A. |e verfasserin |4 aut | |
| 700 | 1 | |a Ulrich, Robert J. |e verfasserin |4 aut | |
| 700 | 1 | |a Walsh, Stephen R. |e verfasserin |4 aut | |
| 700 | 1 | |a Webb, Steve A. |e verfasserin |4 aut | |
| 700 | 1 | |a Weehuizen, Jesper M. |e verfasserin |4 aut | |
| 700 | 1 | |a Velinova, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Hon-Lai |e verfasserin |4 aut | |
| 700 | 1 | |a Wrenn, Rebekah |e verfasserin |4 aut | |
| 700 | 1 | |a Zampieri, Fernando G. |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Wu |e verfasserin |4 aut | |
| 700 | 1 | |a Moher, David |e verfasserin |4 aut | |
| 700 | 1 | |a Goodman, Steven N. |e verfasserin |4 aut | |
| 700 | 1 | |a Ioannidis, John P.A. |e verfasserin |4 aut | |
| 700 | 1 | |a Hemkens, Lars G. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 18. Feb. |
| 773 | 1 | 8 | |g year:2021 |g day:18 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.09.16.20194571 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 18 |c 02 | ||
| 953 | |2 045F |a 570 | ||